Bengaluru, along with Hyderabad, NCR Delhi, and Chennai, is a major hub for these centers, making up 74% of the new ones.

Dr Sanjay Singh, CEO of Gennova Biopharmaceuticals, said the firm will do preclinical and phase 1 vaccine tests in India, where multiple Nipah outbreaks have been reported over the past 20 years.

(Image Credits: Pixabay) Gennova Biopharmaceuticals Ltd. on Tuesday announced that it is partnering with the Coalition for Epidemic Preparedness Innovations (CEPI), a subsidiary of Emcure ...

Currently there are no authorized vaccines or targeted drugs against Nipah, which kills an estimated 75% of those it infects.